NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI) today reported financial results for the quarter ended March 31, 2007. Total revenues for the first quarter of 2007 were approximately $14.3 million, including $11.1 million in net sales of Oracea(R), compared to approximately $3.7 million in the first quarter of 2006, which included no sales of Oracea. Oracea, the Company’s flagship drug for the treatment of rosacea, was approved by the FDA in May 2006 and successfully launched to the U.S. dermatology community in July 2006.
